| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 189.7 | 276.5 | 145.1 |
| Other income | 2.6 | 3.5 | 2.7 |
| Total income | 192.4 | 280.0 | 147.7 |
| Profit before exceptional items & tax | 40.8 | 92.1 | 47.4 |
| Profit before tax | 40.8 | 92.1 | 47.4 |
| Net profit | 24.0 | 74.2 | 34.8 |
| Operating margin | 21.2% | 32.9% | 32.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -31.00% |
|---|---|
| Net profit, quarter on quarter | -67.70% |
| Revenue, year on year | +30.70% |
| Operating profit, year on year | -14.50% |
| Operating profit, quarter on quarter | -56.90% |
BSE results filing, NSE: SUPRIYA. Figures extracted from the filing.
Supriya Lifescience Ltd: key numbers
- Share price
- ₹985.20
- Market cap
- ₹7,929 Cr
- Revenue (annual)
- ₹827.9 Cr
- Net profit (annual)
- ₹209.1 Cr
- P/E (TTM)
- 40.0×Sector 50.4×
- Promoter holding
- 68.30%+0.00% QoQ
- FII holding
- 6.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Supriya Lifescience Ltd
All →Supriya Lifescience Annual General Meeting
Supriya Lifescience Limited conducted its 18th Annual General Meeting on September 24, 2026. All resolutions proposed in the meeting were passed with the requisite majority.
Supriya Lifescience Legal & Regulatory
Bombay High Court ordered provisional release of 200 kg Ketamine Hydrochloride consignment subject to ₹0.72 Crore deposit. Criminal and NDPS proceedings continue.
- Value
- ₹0.72 Cr
Supriya Lifescience Results Correction
Supriya Lifescience explained missing segment details in its Q2 FY27 quick results filing. The omission was a technical XBRL display error; the company operates in one segment.
Supriya Lifescience Other Announcement
The company informs exchanges that it has dispatched communication regarding the Annual Report web link to shareholders with unregistered email IDs.
Supriya Lifescience Legal & Regulatory
Supriya Lifescience Limited informed stock exchanges that there have been no new developments regarding ongoing judicial proceedings involving its General Manager.
Supriya Lifescience Earnings Call Transcript: Key Takeaways
Supriya Lifescience is pivoting to Finished Dosage Forms (FDF) and R&D-driven specialized therapies with a new dedicated manufacturing unit. Focus is on high-margin Anaesthetic, Anti-diabetic, and CNS portfolios.